Identification of cereblon-binding proteins and relationship with response and survival after IMiDs in multiple myeloma. - Wikidata - awgldk - TriplyDB

Identification of cereblon-binding proteins and relationship with response and survival after IMiDs in multiple myeloma.

Identification of cereblon-binding proteins and relationship with response and survival after IMiDs in multiple myeloma.

http://www.wikidata.org/entity/Q33948719

about

Targeted Therapies in Adult B-Cell Malignancies Synergistic Cytotoxicity of Lenalidomide and Dexamethasone in Mantle Cell Lymphoma via Cereblon-dependent Targeting of the IL-6/STAT3/PI3K Axis RNA interference screening identifies lenalidomide sensitizers in multiple myeloma, including RSK2.Rational combination treatment with histone deacetylase inhibitors and immunomodulatory drugs in multiple myeloma.Clinical and pharmacodynamic analysis of pomalidomide dosing strategies in myeloma: impact of immune activation and cereblon targets.Rate of CRL4(CRBN) substrate Ikaros and Aiolos degradation underlies differential activity of lenalidomide and pomalidomide in multiple myeloma cells by regulation of c-Myc and IRF4.Pomalidomide in combination with dexamethasone results in synergistic anti-tumour responses in pre-clinical models of lenalidomide-resistant multiple myeloma.Expression of the cereblon binding protein argonaute 2 plays an important role for multiple myeloma cell growth and survival.A novel effect of thalidomide and its analogs: suppression of cereblon ubiquitination enhances ubiquitin ligase function The IMiDs targets IKZF-1/3 and IRF4 as novel negative regulators of NK cell-activating ligands expression in multiple myeloma Differential effects of lenalidomide during plasma cell differentiation Front-line lenalidomide therapy in patients with newly diagnosed multiple myeloma.Prognostic indicators of lenalidomide for multiple myeloma: consensus and controversy.Immunohistochemical expression of cereblon and MUM1 as potential predictive markers of response to lenalidomide in extranodal marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue (MALT lymphoma).PU.1 acts as tumor suppressor for myeloma cells through direct transcriptional repression of IRF4.Mitochondrial cereblon functions as a Lon-type protease.A calcium- and calpain-dependent pathway determines the response to lenalidomide in myelodysplastic syndromes Transcription factor IKZF1 is degraded during the apoptosis of multiple myeloma cells induced by kinase inhibition.Cereblon in health and disease.The molecular mechanism of thalidomide analogs in hematologic malignancies.Second primary malignancies in multiple myeloma: an overview and IMWG consensus.IKAROS expression in distinct bone marrow cell populations as a candidate biomarker for outcome with lenalidomide-dexamethasone therapy in multiple myeloma.IKZF1 expression is a prognostic marker in newly diagnosed standard-risk multiple myeloma treated with lenalidomide and intensive chemotherapy: a study of the German Myeloma Study Group (DSMM).Immunomodulatory Drugs in Multiple Myeloma: Mechanisms of Action and Clinical Experience.Targeted sequencing of refractory myeloma reveals a high incidence of mutations in CRBN and Ras pathway genes.Role of gut flora after bone marrow transplantation.Lenalidomide increases human dendritic cell maturation in multiple myeloma patients targeting monocyte differentiation and modulating mesenchymal stromal cell inhibitory properties Mouse Monoclonal Antibodies Generated from Full Length Human Cereblon: Detection of Cereblon Protein in Patients with Multiple Myeloma.Mechanisms of Drug Resistance in Relapse and Refractory Multiple Myeloma.Synergistic targeting of Sp1, a critical transcription factor for myeloma cell growth and survival, by panobinostat and proteasome inhibitors High IKZF1/3 protein expression is a favorable prognostic factor for survival of relapsed/refractory multiple myeloma patients treated with lenalidomide.Proteasome inhibitors block Ikaros degradation by lenalidomide in multiple myeloma.Promising therapies in multiple myeloma.Immunomodulatory drugs disrupt the cereblon-CD147-MCT1 axis to exert antitumor activity and teratogenicity.The anti-tumoral effect of lenalidomide is increased in vivo by hypoxia-inducible factor (HIF)-1α inhibition in myeloma cells.Knockdown of CUL4A inhibits invasion and induces apoptosis in osteosarcoma cells.Cereblon: A Protein Crucial to the Multiple Functions of Immunomodulatory Drugs as well as Cell Metabolism and Disease Generation.Lenalidomide and secondary acute lymphoblastic leukemia: a case series.Flavopiridol enhances ABT-199 sensitivity in unfavourable-risk multiple myeloma cells in vitro and in vivo.Prognostic impact of Ikaros expression in lenalidomide-treated multiple myeloma.

P2860

Q26783195-02D6921A-CDA9-46D8-8930-1CBEE7946B1B Q33817800-56049CDC-7883-4FE1-B1DD-8EE760AFD3FC Q34974049-850E52D9-463B-4976-967F-AC8F86AB1667 Q35764582-21BBF577-5AA7-493D-864E-27218D44EE07 Q35784505-781AC758-F0CB-40AB-A624-2048EB3B0CC1 Q35796527-B0FFA1F4-8A52-410E-86FD-21B10B118E46 Q35935794-A5E0DB09-532E-4A27-A728-E1987EF6ECAD Q36007765-AC399F8D-17E4-49CA-A71A-0F5D037D0D3E Q36299827-47656B56-C790-4950-9BB7-E174687081CA Q36414249-081B4FEE-3E44-4070-980C-A0B2977F1328 Q37317494-011D7B75-840F-46F7-A76F-4D6017B7DDCE Q38413040-E834A22D-48FA-40E8-AEDB-7BED9B93DD5D Q38462720-44247D3B-9087-4BEB-81A6-2903A6CE53C6 Q38612199-857C555B-1616-47DA-BEDA-7CECFAE5D3CA Q38709281-938719BF-8DE7-4195-9C40-D89EE48F84BA Q38758114-C05E7747-036D-489A-B6E2-8C351082BE05 Q38764824-A839E499-24D3-46AF-943C-5670E31C94AF Q38852158-4E366D69-A692-46EA-9489-3E5F4C1E8618 Q38876495-F91557B5-FCAA-4FEB-8948-3BEFF9E7B8DB Q38919111-B6C6D629-5BFF-4A5B-84F5-EFEA0FF74118 Q39013620-4F061156-76A9-402E-9167-DB08632A011A Q39040840-FBEAABC2-2284-491B-A524-0C8955529729 Q39065368-D90B2EDE-B349-452D-AD72-F4F6025B6B53 Q39138108-2A7AF9E6-52F6-4396-87CA-F88D564DE69B Q39560208-B92472CE-CB33-4599-8586-6F2BD4935B59 Q41115262-A30ECDD5-C2FF-41C1-A653-83DE9B61BEA4 Q41593035-D4A691B3-0387-4BCA-B74A-035C5416577A Q41660363-FFC444C9-A071-414D-BC10-652B416097C8 Q41770950-B1066E44-14A4-463F-BE00-7E0745C50A59 Q42316993-6077FA97-03D5-4C48-A676-E562B629BDF7 Q42364304-FD873FFF-44BE-4DC3-A56B-FF981AED4D38 Q42399854-22A016AF-1EF2-44BD-BE7D-9EBA907FB559 Q42581682-068E69FF-D082-4E03-9F4F-6091D2767C1D Q42696060-ED16327B-6D08-4480-8F6F-C5558FC47859 Q42923841-B506F40B-C7C1-4101-9542-C7DFA188C131 Q43742227-A29039BA-2B7F-488E-A0E9-AC5DD549B54B Q46054966-CC042930-0574-4F95-940F-A7A280A69C8A Q46408789-FD672582-AE62-4825-9CB3-7A14AD2E1E43 Q46640442-873A4859-FD44-4F2F-8C7E-6BDDB223B2DB Q47141507-5E488F73-4408-42BC-A811-BAA62C466AB8

P2860

Identification of cereblon-binding proteins and relationship with response and survival after IMiDs in multiple myeloma.

http://www.wikidata.org/entity/Q33948719

description

2014 nî lūn-bûn

@nan

2014 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Identification of cereblon-bin ...... ter IMiDs in multiple myeloma.

@ast

Identification of cereblon-bin ...... ter IMiDs in multiple myeloma.

@en

type

label

Identification of cereblon-bin ...... ter IMiDs in multiple myeloma.

@ast

Identification of cereblon-bin ...... ter IMiDs in multiple myeloma.

@en

prefLabel

Identification of cereblon-bin ...... ter IMiDs in multiple myeloma.

@ast

Identification of cereblon-bin ...... ter IMiDs in multiple myeloma.

@en

P1433

Q33948719-3DB48476-31FA-463F-88DD-BCF8EC4DA3F2

P1476

Q33948719-EC5D3EE3-1647-45B7-AD5F-26AC664BA6C1

P2093

Q33948719-0AF4987F-9201-4619-A259-EA109FE2CBE9

Q33948719-16D47017-AA5A-4593-A438-3330240B0E81

Q33948719-2FF017D7-30DA-412A-B704-934AD3E9D302

Q33948719-432E6A66-9E6D-4B13-AF2E-3179C1A2CCD9

Q33948719-67314F84-154C-42A9-A518-565D32AC985C

Q33948719-6A10676B-1B7A-4B58-8D44-D8D88D82A84F

Q33948719-6CC0DD6A-2B9F-4955-89FB-4698A1529543

Q33948719-7F6507EA-6398-4442-BF99-26F3F08F1D37

Q33948719-89DE1394-FEBF-42EF-8593-D712D69F8C7C

Q33948719-8CA7F8B9-4657-428C-9D72-33956D6B41BE

P2860

Q33948719-14162517-4837-4BF0-B9BD-FA7C15BE7FD2

Q33948719-17A8544E-99D2-44CF-BA48-5105A6990D8B

Q33948719-1A8F21E2-F427-4771-B811-5B7498910C67

Q33948719-39B1297C-BFFC-4E90-8842-7BE08C830EC3

Q33948719-39C3F3FD-9984-4198-9BB7-ED6BB1CFDD83

Q33948719-3FAF9C27-6AEF-4769-A3A3-A888F12C6183

Q33948719-420F2C7F-8458-49BA-92BE-02F4DFB60DB2

Q33948719-421477D3-DD75-4994-A02C-CAE66DD08B26

Q33948719-44A1B5DB-0644-4F08-A49C-88BEA5D82BE2

Q33948719-4B33718D-96D6-4B33-B638-17B759710C79

P304

Q33948719-99C61210-8B35-425E-A351-FE6D53358464

P31

Q33948719-97C7E716-4523-4E8F-8732-1D3AD9F423FE

P356

Q33948719-030BFBD8-7EB6-4FC6-929E-4FD81EA33C91

P407

Q33948719-0A4962D9-FEDE-46A9-A31B-E1E4CC368C33

P433

Q33948719-B5F3AD5C-5F1A-45C5-89FD-754C79602153

P478

Q33948719-5AC07AFC-C2DB-496E-94A6-01963014EDE0

P50

Q33948719-042F8631-D390-4C71-B309-03D1C37A68E3

P577

Q33948719-30F557F6-30AD-4DBE-A1E1-3E64E5CE1F65

P5875

Q33948719-E31AF9B3-8D82-477E-9F21-F802B35C7EE8

P698

Q33948719-61A0360D-6900-4C87-8ED5-849153D2AEDF

P932

Q33948719-7F16F7FF-EA4F-480C-AC35-E9AD4AEB5EDF

P356

BLOOD-2014-02-557819

P1433

P1476

Identification of cereblon-bin ...... ter IMiDs in multiple myeloma.

@en

P2093

A Keith Stewart

http://www.w3.org/2001/XMLSchema#string

Betsy LaPlant

http://www.w3.org/2001/XMLSchema#string

Chang-Xin Shi

http://www.w3.org/2001/XMLSchema#string

Esteban Braggio

http://www.w3.org/2001/XMLSchema#string

Jessica E Schmidt

http://www.w3.org/2001/XMLSchema#string

Joseph Mikhael

http://www.w3.org/2001/XMLSchema#string

K Martin Kortuem

http://www.w3.org/2001/XMLSchema#string

Kristina Laumann

http://www.w3.org/2001/XMLSchema#string

Laura A Bruins

http://www.w3.org/2001/XMLSchema#string

Mia D Champion

http://www.w3.org/2001/XMLSchema#string

P2860

Identification of a primary target of thalidomide teratogenicity

The Ikaros gene encodes a family of lymphocyte-restricted zinc finger DNA binding proteins, highly conserved in human and mouse

Combinatorial effects of splice variants modulate function of Aiolos

Aiolos, a lymphoid restricted transcription factor that interacts with Ikaros to regulate lymphocyte differentiation

Thalidomide is an inhibitor of angiogenesis

Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide

Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma

BSAP (Pax5)-importin alpha 1 (Rch1) interaction identifies a nuclear localization sequence

Ikaros DNA-binding proteins direct formation of chromatin remodeling complexes in lymphocytes

The myeloma drug lenalidomide promotes the cereblon-dependent destruction of Ikaros proteins

P304

536-545

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1182/BLOOD-2014-02-557819

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

124

http://www.w3.org/2001/XMLSchema#string

P50

P577

2014-06-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

262979479

http://www.w3.org/2001/XMLSchema#string

P698

24914135

http://www.w3.org/2001/XMLSchema#string

P932

4110660

http://www.w3.org/2001/XMLSchema#string